ijo
www.spandidos-publications.com
Home  | About  | Contact
Spandidos Logo
Advanced Search
Login  | Register


congress_banner

main_table_top_image
   Current Issue Early Online Archive Manuscript Submission About Editor and Editorial Academy Sitemap
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2

Authors:
Oscar B. Goodman, Sonali P. Barwe, Brigitte Ritter, Peter S. McPherson, Ann-Jeanette Vasko, James H. Keen, David M. Nanus, Neil H. Bander, Ayyappan K. Rajasekaran

Affiliations:
Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University-New York Presbyterian Hospital, New York, NY, USA

Pages:
1199-1203

Abstract:

Prostate-specific membrane antigen (PSMA) is an integral membrane glycoprotein expressed in prostatic epithelia and is being evaluated as a therapeutic target in prostate cancer. It undergoes constitutive receptor-mediated endocytosis via clathrin-coated pits, which is enhanced in the presence of monoclonal antibodies directed against it. We describe distinct interactions of PSMA with clathrin and the clathrin adaptor protein-2 (AP-2) complex, two components of clathrin-coated pits. The intracellular N-terminal domain of PSMA interacts with the N-terminal globular domain of clathrin heavy chain. Deletion analysis revealed an important determinant of this interaction residing within the proximal portion of the clathrin heavy chain N-terminal domain (amino acids 1-85) distinct from the clathrin binding sites of other known clathrin-binding proteins. Furthermore, PSMA interacts with the ear domain of α-adaptin (an AP-2 subunit), and a glutamic acid residue at position 7 in the cytoplasmic tail of PSMA is essential for this interaction. These data indicate that PSMA exhibits a high affinity, specific association with the clathrin-based endocytic machinery by distinct interactions with both clathrin and AP-2. Thus, although PSMA is a new member of the dual AP and clathrin binding proteins, its α-adaptin and clathrin heavy chain binding determinants are distinct from those of other members.

International Journal of Oncology

November 2007
Volume 31 Number 5


Viewing options: Sign up for eToc alerts

Share this article:



main_table_bottom_image